Adriamycin

Phase 3Small molecule

HHRYZ Biotech Co.

Adriamycin is one of 145 small molecule programs targeting Soft Tissue Sarcoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

144

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft Tissue SarcomaUnknown status

Multiple MyelomaActive, not recruiting

Advanced Hodgkin LymphomaActive, not recruiting

SarcomaCompleted

TrialActive, not recruiting

Inflammatory Breast CancerActive, not recruiting

RemissionActive, not recruiting

Soft Tissue SarcomaPhase 2

Unknown status

Multiple MyelomaPhase 3

Active, not recruiting

Advanced Hodgkin LymphomaPhase 2

Active, not recruiting

SarcomaPreclinical

Completed

TrialPhase 2

Active, not recruiting

Inflammatory Breast CancerPhase 2

Active, not recruiting

RemissionPhase 2

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

47 2

Ninlaro

Takeda

Phase 3

18 3

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 4

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 5

Elranatamab

Pfizer

Phase 3

27 6

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

10 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 8

Velcade

Takeda

Phase 3

28 9

G-CSF

AArog Pharmaceuticals, Inc.

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Advanced Hodgkin Lymphoma

NCT03517137

Phase 2Active, not recruiting

Trial

NCT00871013

Phase 2Active, not recruiting

Inflammatory Breast Cancer

NCT02623972

Q3 2027

Phase 3Active, not recruiting

Study completion

NCT00572169

Q4 2027

Phase 2Active, not recruiting

Remission

NCT00869232

Q4 2028

Phase 2Active, not recruiting

Multiple Myeloma

NCT03004287

Clinical

Trials by Indication[1]

Breast Cancer6 trials

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Completed·—·Phase 2·NCT00136539·41 enrolled

A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001384·35 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Completed·NNSABP Foundation Inc·Phase 3·NCT00087178·2,722 enrolled

Show 3 more trials

Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient

Unknown status·NNational University Hospital, Singapore·Phase 2·NCT00669773·49 enrolled

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT00003352·89 enrolled

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Completed·NNSABP Foundation Inc·Phase 3·NCT00004067·2,130 enrolled

Acute Lymphoblastic Leukemia5 trials

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed·GGoethe University·Phase 4·NCT00198991·1,883 enrolled

Show 2 more trials

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Completed·GGoethe University·Phase 4·NCT00199056·225 enrolled

Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00199095·40 enrolled

Lymphoma5 trials

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT03004833·110 enrolled

Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

Completed·NNicola Goekbuget·Phase 4·NCT00199082·650 enrolled

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT02505269·34 enrolled

Show 2 more trials

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Unknown status·KKing Abdullah International Medical Research Center·Phase 2·NCT03527628·220 enrolled

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00352027·81 enrolled

Multiple Myeloma4 trials

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Unknown status·KKorean Multiple Myeloma Working Party·Phase 2·NCT00319865·47 enrolled

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00441168·30 enrolled

Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients

Completed·MMeletios A. Dimopoulos·Phase 2·NCT02471820·45 enrolled

Show 1 more trial

2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

Soft Tissue Sarcoma4 trials

Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT00204646

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04910126·84 enrolled

A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06367075·53 enrolled

Show 1 more trial

Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)

Unknown status·UUniversity Hospital Schleswig-Holstein·Phase 2·NCT00204568·117 enrolled

21 more indications

Prognosis2 trials

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099188·27 enrolled

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099175·41 enrolled

Age2 trials

HD11 for Intermediate Stages

Completed·UUniversity of Cologne·Phase 3·NCT00264953·1,395 enrolled

HD10 for Early Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265018·1,370 enrolled

Dexamethasone2 trials

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

Completed·UUniversity of Arkansas·Phase 3·NCT00083915·97 enrolled

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 3·NCT00215943·90 enrolled

Chidamide2 trials

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03553238·70 enrolled

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564704·80 enrolled

Hodgkin's Disease2 trials

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038558·25 enrolled

Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01404936·35 enrolled

Chemotherapy1 trial

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Completed·MM.D. Anderson Cancer Center·N/A·NCT00410488·51 enrolled

Advanced Stage1 trial

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

Sarcoma1 trial

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

Completed·MM.D. Anderson Cancer Center·N/A·NCT00283621·51 enrolled

Dendritic Cell1 trial

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

Completed·UUniversity of Arkansas·Phase 2·NCT00083538·40 enrolled

Brentuximab Vedotin1 trial

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02298283·40 enrolled

Efficacy1 trial

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00267046·49 enrolled

Lymphoblastic Lymphoma1 trial

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199017·75 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors

Terminated·HHRYZ Biotech Co.·Phase 1·NCT03034304·105 enrolled

Remission1 trial

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00869232·90 enrolled

Trial1 trial

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT00871013·160 enrolled

Neuroblastoma1 trial

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Completed·—·Phase 2·NCT00165139·20 enrolled

Advanced Malignancy1 trial

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00147225·55 enrolled

Solitary Fibrous Tumor1 trial

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Completed·IItalian Sarcoma Group·Phase 2·NCT03023124·23 enrolled

Advanced Hodgkin Lymphoma1 trial

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03517137·150 enrolled

Inflammatory Breast Cancer1 trial

A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Active, not recruiting·DDana-Farber Cancer Institute·Phase 2·NCT02623972·22 enrolled

Unspecified2 trials

Rituximab and ABVD for Hodgkin's Patients

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00504504·85 enrolled

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 3·NCT00572169·177 enrolled

Sources

References

[1]
ClinicalTrials.gov — 51 trial records for Adriamycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adriamycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adriamycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HRYZ Biotech Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHRYZ Biotech Co.

Adriamycin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Breast Cancer6 trials

Acute Lymphoblastic Leukemia5 trials

Lymphoma5 trials

Multiple Myeloma4 trials

Soft Tissue Sarcoma4 trials

Prognosis2 trials

Age2 trials

Dexamethasone2 trials

Chidamide2 trials

Hodgkin's Disease2 trials

Chemotherapy1 trial

Advanced Stage1 trial

Sarcoma1 trial

Dendritic Cell1 trial

Brentuximab Vedotin1 trial

Efficacy1 trial

Lymphoblastic Lymphoma1 trial

Patients With Advanced Solid Tumors1 trial

Remission1 trial

Trial1 trial

Neuroblastoma1 trial

Advanced Malignancy1 trial

Solitary Fibrous Tumor1 trial

Advanced Hodgkin Lymphoma1 trial

Inflammatory Breast Cancer1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News